ATYR PHARMA INC (ATYR) Stock Fundamental Analysis
USA - NASDAQ:ATYR - US0021202025 - Common Stock
0.7819 USD
-0.01 (-1.03%)
Overall ATYR gets a fundamental rating of 2 out of 10. We evaluated ATYR against 531 industry peers in the Biotechnology industry. ATYR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ATYR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ATYR had negative earnings in the past year.
ATYR had a negative operating cash flow in the past year.
ATYR had negative earnings in each of the past 5 years.
ATYR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ATYR has a Return On Assets of -70.44%. This is in the lower half of the industry: ATYR underperforms 61.39% of its industry peers.
The Return On Equity of ATYR (-93.63%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.44% | ||
| ROE | -93.63% | ||
| ROIC | N/A |
ROA(3y)-51.74%
ROA(5y)-45.27%
ROE(3y)-70.15%
ROE(5y)-58.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ATYR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ATYR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ATYR has more shares outstanding
ATYR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ATYR has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -7.58, we must say that ATYR is in the distress zone and has some risk of bankruptcy.
ATYR's Altman-Z score of -7.58 is on the low side compared to the rest of the industry. ATYR is outperformed by 67.98% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ATYR is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, ATYR is in line with its industry, outperforming 46.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.58 |
ROIC/WACCN/A
WACC8.7%
2.3 Liquidity
ATYR has a Current Ratio of 5.93. This indicates that ATYR is financially healthy and has no problem in meeting its short term obligations.
ATYR has a better Current ratio (5.93) than 63.28% of its industry peers.
ATYR has a Quick Ratio of 5.93. This indicates that ATYR is financially healthy and has no problem in meeting its short term obligations.
ATYR has a Quick ratio of 5.93. This is in the better half of the industry: ATYR outperforms 63.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.93 | ||
| Quick Ratio | 5.93 |
3. Growth
3.1 Past
ATYR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.70%, which is quite good.
Looking at the last year, ATYR shows a very negative growth in Revenue. The Revenue has decreased by -19.15% in the last year.
Measured over the past years, ATYR shows a very negative growth in Revenue. The Revenue has been decreasing by -11.05% on average per year.
EPS 1Y (TTM)11.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.04%
Revenue 1Y (TTM)-19.15%
Revenue growth 3YN/A
Revenue growth 5Y-11.05%
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 22.36% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 304.51% on average over the next years. This is a very strong growth
EPS Next Y13.83%
EPS Next 2Y14.19%
EPS Next 3Y16.82%
EPS Next 5Y22.36%
Revenue Next Year548.65%
Revenue Next 2Y923%
Revenue Next 3Y619.56%
Revenue Next 5Y304.51%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ATYR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATYR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ATYR's earnings are expected to grow with 16.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.19%
EPS Next 3Y16.82%
5. Dividend
5.1 Amount
ATYR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ATYR (11/11/2025, 9:56:59 AM)
0.7819
-0.01 (-1.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners68.69%
Inst Owner ChangeN/A
Ins Owners2.01%
Ins Owner Change0%
Market Cap76.62M
Revenue(TTM)190.00K
Net Income(TTM)-75.12M
Analysts74.12
Price Target10.31 (1218.58%)
Short Float %37.42%
Short Ratio2.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.87%
Min EPS beat(2)-38.81%
Max EPS beat(2)-16.94%
EPS beat(4)2
Avg EPS beat(4)-5.39%
Min EPS beat(4)-38.81%
Max EPS beat(4)21.92%
EPS beat(8)4
Avg EPS beat(8)-2.16%
EPS beat(12)8
Avg EPS beat(12)7.83%
EPS beat(16)9
Avg EPS beat(16)2.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-47.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-19.77%
EPS NY rev (1m)0.27%
EPS NY rev (3m)-10.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-22.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-20%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 403.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.95 | ||
| P/tB | 0.95 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0
BVpS0.82
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.44% | ||
| ROE | -93.63% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-51.74%
ROA(5y)-45.27%
ROE(3y)-70.15%
ROE(5y)-58.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | -21.19% | ||
| Cap/Sales | 37.37% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.93 | ||
| Quick Ratio | 5.93 | ||
| Altman-Z | -7.58 |
F-Score3
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)476.17%
Cap/Depr(5y)300.89%
Cap/Sales(3y)412.5%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.04%
EPS Next Y13.83%
EPS Next 2Y14.19%
EPS Next 3Y16.82%
EPS Next 5Y22.36%
Revenue 1Y (TTM)-19.15%
Revenue growth 3YN/A
Revenue growth 5Y-11.05%
Sales Q2Q%N/A
Revenue Next Year548.65%
Revenue Next 2Y923%
Revenue Next 3Y619.56%
Revenue Next 5Y304.51%
EBIT growth 1Y-15.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.76%
EBIT Next 3Y2.84%
EBIT Next 5Y31.91%
FCF growth 1Y-66.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-93.44%
OCF growth 3YN/A
OCF growth 5YN/A
ATYR PHARMA INC / ATYR FAQ
What is the ChartMill fundamental rating of ATYR PHARMA INC (ATYR) stock?
ChartMill assigns a fundamental rating of 2 / 10 to ATYR.
What is the valuation status of ATYR PHARMA INC (ATYR) stock?
ChartMill assigns a valuation rating of 0 / 10 to ATYR PHARMA INC (ATYR). This can be considered as Overvalued.
How profitable is ATYR PHARMA INC (ATYR) stock?
ATYR PHARMA INC (ATYR) has a profitability rating of 0 / 10.
Can you provide the financial health for ATYR stock?
The financial health rating of ATYR PHARMA INC (ATYR) is 4 / 10.
What is the earnings growth outlook for ATYR PHARMA INC?
The Earnings per Share (EPS) of ATYR PHARMA INC (ATYR) is expected to grow by 13.83% in the next year.